text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 150399-21-6 | Product Number: B4121

Balsalazide Disodium Salt Dihydrate


Purity: >98.0%(HPLC)(N)
Synonyms:
  • 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic Acid Disodium Salt Dihydrate
Documents:
1G
$86.00
Contact Us Contact Us Contact Us
5G
$282.00
2   1   2  

* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.


Product Number B4121
Purity / Analysis Method >98.0%(HPLC)(N)
Molecular Formula / Molecular Weight C__1__7H__1__3N__3Na__2O__6·2H__2O = 437.32  
Physical State (20 deg.C) Solid
CAS RN 150399-21-6
Related CAS RN 82101-18-6&399030-81-0
PubChem Substance ID 253659991
Merck Index (14) 945
MDL Number

MFCD01631117

Specifications
Appearance Light yellow to Brown powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(with Total Nitrogen) min. 98.0 %(calcd.on anh.substance)
Water 7.0 to 11.0 %
Properties (reference)
Solubility in water Completely soluble
Solubility (very slightly) Ethanol,Methanol
GHS
Related Laws:
Transport Information:
HS Number 2927.00.5000
Application
A Pro-Drug of 5-Aminosalicylic Acid, Balsalazide

Balsalazide is the prodrug of 5-aminosalicylic acid [A0317] and 4-aminobenzoyl-beta-alanine (an inert carrier), which are released by bacterial enzymes in the colon.

References

  • Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats
    • I. Kimura, M. Kawasaki, S. Nagahama, A. Matsuda, M. Kataoka, Y. Kokuba, Arzneim.-Forsch. 1998, 48, 1091.
  • Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine
    • I. Kimura, T. Kumamoto, A. Matsuda, M. Kataoka, Y. Kokuba, Arzneim.-Forsch. 1998, 48, 1007.


PubMed Literature


TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents